Table 4. Comparison of autoantibodies to MUC1 glycoforms in cases of breast cancer taken up to 3 years before diagnosis vs controls.
| (A) Discovery set | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
|
MUC1 glycoforms
P-value breast cancer cases
vs
controls |
||||||||
| Time to diagnosis in years | No. of sera | MUC1 ungly | MUC1 unglyRec | MUC1core3 | MUC1STn | MUC1T | MUC1TRec | MUC1Tn | MUC1TnRec | MUC1STRec |
| 0–1 |
93 |
0.245 |
0.598 |
0.124 |
0.374 |
0.362 |
0.560 |
0.171 |
0.418 |
0.299 |
| 1–2 |
90 |
0.121 |
0.409 |
0.024 |
0.311 |
0.373 |
0.359 |
0.320 |
0.453 |
0.204 |
| 2–3 | 74 | 0.347 | 0.110 | 0.185 | 0.583 | 0.251 | 0.322 | 0.763 | 0.961 | 0.331 |
|
(B) Validation set | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| UKCTOCS cohort | |||||||||
| |
|
MUC1 glycoforms
P-value breast cancer cases
vs
controls |
|||||||
| Time to diagnosis in years | No. of sera | MUC1 ungly | MUC1 ungly Rec | MUC1core3 | MUC1STn | MUC1TRec | MUC1Tn | MUC1TnRec | MUC1STRec |
| 0–1 |
133 |
0.793 |
0.340 |
0.386 |
0.842 |
0.721 |
0.789 |
0.762 |
0.799 |
| 1–2 |
87 |
0.391 |
0.661 |
0.364 |
0.458 |
0.639 |
0.887 |
0.942 |
0.591 |
| 2–3 | 94 | 0.155 | 0.763 | 0.484 | 0.472 | 0.334 | 0.435 | 0.559 | 0.477 |
| Guernsey cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| |
|
MUC1 glycoforms
P-value breast cancer cases
vs
all controls |
|||||||
| Time to diagnosis in years | No. of sera | MUC1 ungly | MUC1 ungly Rec | MUC1core3 | MUC1STn | MUC1TRec | MUC1Tn | MUC1TnRec | MUC1STRec |
| 0–3 | 42 | 0.594 | 0.520 | 0.957 | 0.311 | 0.834 | 0.453 | 0.527 | 0.435 |
Abbreviation: UKCTOCS=UK Collaborative Trial of Ovarian Cancer Screening.